Castle Biosciences Inc (Nasdaq: CSTL), a provider of diagnostic testing for skin cancers and other conditions, announced on Friday that it will present new data on its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting in Chicago, from 7-10 November.

Study author Dr Etan Marks will lead poster presentations during a defense session on 9 November.

DecisionDx-Melanoma, a 31-gene expression profile test, assists in stratifying recurrence risk in cutaneous melanoma and evaluating sentinel lymph node positivity. Supported by over 50 peer-reviewed studies and 183,000 test orders to date, it is a validated tool for personalised risk assessment and improved disease management.

MyPath Melanoma, a 23-gene expression test, aids in the accurate characterisation of challenging melanocytic lesions. With approximately 300,000 biopsied cases annually lacking clear classification through traditional methods, MyPath provides objective analysis to help inform treatment decisions and reduce diagnostic uncertainty.

Castle Biosciences focuses on enhancing patient care through innovative solutions and is advancing tests for additional high-need medical areas.